Skip to content
ExperimentalMitochondrialOralDailyCarcinogenicity signal in rodentsPartial data

Cardarine

GW501516

PPARδ agonist that increases fatty-acid oxidation and endurance in preclinical models. Development halted over carcinogenicity findings in rats.

◆ Editorial note

Non-peptide PPARδ agonist. Included for its metabolic effects that overlap with this category.

§ 01   Overview

Overview

PPARδ agonist that increases fatty-acid oxidation and endurance in preclinical models. Development halted over carcinogenicity findings in rats.

Development discontinued by GSK due to cancer signals in long-term rat studies. WADA-banned at all times.

§ 02   Mechanism

Mechanism of action

Cardarine activates PPARδ, a nuclear receptor that upregulates genes involved in fatty-acid oxidation, mitochondrial biogenesis, and endurance. It does not bind to any peptide receptor.

  • 01Improved endurance in preclinical models
  • 02Increased fatty-acid oxidation
  • 03Lipid profile improvements in early human studies

§ 03   Dosing

Dosing protocol

Standard Protocol

Dose Range
10 – 20 mg daily (research)
Route
Oral
Frequency
Daily
Cycle
Short cycles 4–8 weeks at most

§ 04   Evidence

Evidence & research

Experimental

Development discontinued by GSK due to cancer signals in long-term rat studies. WADA-banned at all times.

FDA Status

Not FDA-approved. WADA prohibited.

§ 06   News

In the news

8 articles from the last 12 months · updates hourly

§ 07   Sourcing

Sourcing & supply

Regulatory status

Research-only, no commercial channel

No commercial channel exists. Available only as a research reagent from RUO suppliers. Use in humans is not established.

No suppliers in our directory currently stock this compound. For investigational or research-only compounds, legitimate channels may not exist outside clinical trials.

Browse full supplier directory

§ 09   Safety

Safety & side effects

Side effects

  • 01Long-term carcinogenicity concern
  • 02Unknown human safety profile

Contraindications

  • 01Personal or family cancer history
  • 02Pregnancy

§ 10   Questions

Cardarine FAQ

What is Cardarine?
PPARδ agonist that increases fatty-acid oxidation and endurance in preclinical models. Development halted over carcinogenicity findings in rats. Cardarine activates PPARδ, a nuclear receptor that upregulates genes involved in fatty-acid oxidation, mitochondrial biogenesis, and endurance. It does not bind to any peptide receptor.
What is Cardarine used for?
Reported uses include improved endurance in preclinical models, increased fatty-acid oxidation, and lipid profile improvements in early human studies. Evidence strength is rated Experimental — see the evidence section for detail.
How is Cardarine dosed?
Commonly referenced dosing is 10 – 20 mg daily (research), administered Oral. This is educational reference only; consult a licensed clinician before use.
What are the side effects of Cardarine?
Commonly reported side effects include long-term carcinogenicity concern and unknown human safety profile. This list is not exhaustive.
Is Cardarine legal?
No commercial channel exists. Available only as a research reagent from RUO suppliers. Use in humans is not established. FDA status: Not FDA-approved. WADA prohibited..

This site is for educational and research purposes only. It does not constitute medical advice. Always consult a qualified healthcare provider before using any peptide or supplement.